Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies-Reference-Cited by-同舟云学术

Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies

Published:2024-08-15 Issue:16 Volume:16 Page:2854
ISSN:2072-6694
Container-title:Cancers
language:en
Short-container-title:Cancers

Author:

Mo Christiana¹²^ORCID,Sterpi Michelle¹²,Jeon Hyein¹²^ORCID,Bteich Fernand¹²^ORCID

Affiliation:

1. Department of Medical Oncology, Albert Einstein College of Medicine, Bronx, NY 10461, USA

2. Department of Medical Oncology, Montefiore Medical Center, Bronx, NY 10467, USA

Abstract

Human epidermal growth factor 2 (HER2) is a tyrosine kinase receptor that interacts with multiple signaling pathways related to cellular growth and proliferation. Overexpression or amplification of HER2 is linked to various malignancies, and there have been decades of research dedicated to targeting HER2. Despite the landmark ToGA trial, progress in HER2-positive gastrointestinal malignancies has been hampered by drug resistance. This review examines current HER2 expression patterns and therapies for gastroesophageal, colorectal, biliary tract, and small bowel cancers, while dissecting potential resistance mechanisms that limit treatment effectiveness.

Publisher

MDPI AG

Link

https://www.mdpi.com/2072-6694/16/16/2854/pdf

Reference166 articles.

1. Biologic and therapeutic role of HER2 in cancer;Pupa;Oncogene,2003

2. Clinicopathological factors associated with HER2-positive gastric cancer: A meta-analysis;Wang;Medicine,2017

3. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites;Vijayvergia;Cancer Biol. Ther.,2015

4. Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab;Kawamoto;J. Gastroenterol.,2015

5. ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma;Laforest;Eur. J. Cancer,2014